OncoCyte (OCX) Misses Q3 EPS by 98c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- US stock futures rise as investors assess Democrats' midterm sweep
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts OCX Hot Sheet
Join SI Premium – FREE
OncoCyte (NASDAQ: OCX) reported Q3 EPS of ($0.98). Revenue for the quarter came in at $110 thousand.
For earnings history and earnings-related data on OncoCyte (OCX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Marriott Vacations Worldwide (VAC) Tops Q3 EPS by 7c; offers guidance
- SharkNinja (SN) Tops Q3 EPS by 74c; Offers Guidance
- OPENLANE, Inc. (OPLN) Tops Q3 EPS by 5c, Beats on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
